Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Onkologie ; 26(6): 564-7, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14709931

ABSTRACT

BACKGROUND: Inclusion of inguinal lymphadenectomy in the surgical procedure is a potential prognostic factor for squamous cell vulvar carcinoma. PATIENTS AND METHODS: A total of 33 women with early-stage squamous cell vulvar carcinoma were analyzed retrospectively. Before the establishment of FIGO criteria in 1983, 17 patients with stage I and 2 patients with stage II were evaluated clinically without inguinal lymphadenectomy. All patients underwent post-operative radiotherapy with a median dose of 45 Gy to the pelvis (vulva included) and boost dose to the vulva ranging from 10 to 20 Gy. Factors assessed for prognostic value included age, inguinal lymph node dissection, differentiation grade, and total irradiation dose to the vulva and pelvis. RESULTS: The log-rank test and the univariate regression analysis revealed that all above factors except irradiation dose decreased the overall survival. In the multivariate regression analysis, differentiation grade and the absence of inguinal dissection were independent predictors for decreased survival with a relative risk up to 2.6 (95% CI = 1.3, 5.6) and 2.7 (95% CI = 1.31, 5.44), respectively. CONCLUSION: Clinical evaluation of inguinal lymph node involvement is inadequate and node dissection is definitely the only appropriate surgical procedure for vulvar carcinoma.


Subject(s)
Carcinoma, Squamous Cell/surgery , Lymph Node Excision , Vulvar Neoplasms/surgery , Actuarial Analysis , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Combined Modality Therapy , Female , Humans , Inguinal Canal/pathology , Inguinal Canal/surgery , Lymphatic Irradiation , Middle Aged , Neoplasm Staging , Radiotherapy, Adjuvant , Retrospective Studies , Survival Rate , Vulva/pathology , Vulva/surgery , Vulvar Neoplasms/pathology , Vulvar Neoplasms/radiotherapy
2.
Onkologie ; 25(4): 364-9, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12232489

ABSTRACT

PURPOSE: To study the cytoprotective impact of amifostine against acute radiation mucositis. PATIENTS AND METHODS: A total of 117 cancer patients with carcinomas localized in pelvic organs, lung and head and neck were entered into this study. In a retrospective way, and in order to minimize the bias related to the investigator, 138 patients as historical controls were randomly selected from a database in our hospital. Acute radiation-induced gastrointestinal mucositis, esophagitis and stomatitis were assessed using the common toxicity criteria scale. The most severe grade recorded was evaluated as the final morbidity score for this patient. Mean toxicity score (MTS) was the mean value of recorded acute radiation toxicity. Mean interruption time (MIT) was the mean value of recorded interruption time due to radiation toxicity. RESULTS: A significantly reduced severity of symptomatology related to oral, esophageal and rectal mucosa was noted in the amifostine group (group A) (p < 0.05, chi-square test). Furthermore, a significant reduction of MTS as well as MIT was observed in group A versus the historical controls (group B) (p < 0.05, Mann-Whitney U test). CONCLUSION: The administration of amifostine seems to protect patients against radiation-induced mucositis, but further investigation with randomized trials is needed.


Subject(s)
Amifostine/administration & dosage , Esophagus/drug effects , Gastric Mucosa/drug effects , Mouth Mucosa/radiation effects , Neoplasms/radiotherapy , Radiation Injuries/prevention & control , Radiation-Protective Agents/administration & dosage , Stomatitis/prevention & control , Acute Disease , Adult , Aged , Amifostine/adverse effects , Female , Humans , Male , Middle Aged , Neoplasm Staging , Neoplasms/pathology , Radiation Injuries/etiology , Radiation-Protective Agents/adverse effects , Radiotherapy Dosage , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...